Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05654532
• Other study ID #: AC699-001
• Status: Recruiting
• Phase: Phase 1
• Start date: December 29, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: February 2024
• Source: Accutar Biotechnology Inc
• Contact: Accutar Biotechnology, Inc.
• Phone: 908-340-0879
• Email: medical[@]accutarbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to:

• Identify the recommended dose of AC699 that can be given safely to participants

• Evaluate the safety profile of AC699

• Evaluate the pharmacokinetics of AC699

• Evaluate the effectiveness of AC699

Description:

This study is a Phase I, first-in-human, open-label dose-escalation study of AC699, an orally bioavailable estrogen receptor degrader, given as a single agent.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 31, 2024
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed written informed consent (ICF)

• Adult male and female participants, at least 18 years-of-age at the time of signature of the ICF

• Female participants must be postmenopausal

• Confirmed diagnosis of advanced, unresectable, and/or metastatic breast cancer following disease progression on standard treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to standard therapies

• Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive (ER+) human epidermal growth factor 2 negative (HER2-) breast cancer

• Must have received at least 2 prior endocrine or at least 1 prior line of endocrine therapy if combined with CDK4/6 inhibitor

• Prior chemotherapy is not required, but up to 3 prior regimens of cytotoxic chemotherapy will be allowed in the locally advanced/ metastatic setting

• At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Appendix B) or at least 1 predominantly lytic bone lesion in the absence of measurable disease

• Acceptable organ and hematologic function at baseline

• Life expectancy =12 weeks after the start of the treatment

Exclusion Criteria:

• Treatment with any of the following:

• Any cytotoxic chemotherapy, investigational agents or other anti-cancer drugs for the treatment of locally advanced or metastatic breast cancer within 14 days prior to the first administration of AC699

• Radiation therapy within 14 days prior to first study drug administration that did not resolve to tolerable toxicity, or prior irradiation to >25% of bone marrow. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed 7 days prior to study enrollment and no clinically significant toxicities are expected (e.g., mucositis, esophagitis).

• Major surgery within 21 days prior to the first study drug administration (exception: participants may enroll if fully recovered or without intolerable or clinically significant adverse effects but at least 14 days must have elapsed between major surgery and first study drug administration)

• Known symptomatic brain metastases requiring the use of systemic corticosteroids =10 mg/day prednisone or equivalents. Asymptomatic and treated, or asymptomatic untreated brain metastases are allowed as long as participants are clinically stable. Stable doses of anticonvulsants are allowed.

• Any condition that impairs a participant's ability to swallow whole pills. Impairment of gastrointestinal function (GI) or GI disease or other condition at baseline that will interfere significantly with the absorption, distribution, or metabolism of AC699.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• AC699
Participants will receive AC699 orally daily in 28-day cycles.

Locations

Country	Name	City	State
United States	Site 03	Houston	Texas
United States	Site 01	Nashville	Tennessee
United States	Site 05	Norfolk	Virginia
United States	Site 02	Sarasota	Florida
United States	Site 04	Vancouver	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Accutar Biotechnology Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose limiting toxicities (DLTs) from AC699 monotherapy		First 28 days of treatment. Cycles are 28 days.
Primary	Incidence of treatment-emergent adverse events (TEAEs) and clinically significant Grade 3 or higher lab abnormalities following administration of AC699		Approximately 18 months.
Secondary	Objective response rate (ORR) to assess the anti-tumor activity of AC699		Approximately 18 months.
Secondary	Clinical Benefit Rate (CBR) to assess the anti-tumor activity of AC699 using RECIST 1.1		Approximately 18 months.
Secondary	Duration of Response (DOR) to assess the anti-tumor activity of AC699 using RECIST 1.1		Approximately 18 months.
Secondary	Disease Control Rate (DCR) to assess the anti-tumor activity of AC699 using RECIST 1.1		Approximately 18 months.
Secondary	Progression Free Survival (PFS) to assess the anti-tumor activity of AC699 using RECIST 1.1		Approximately 18 months.
Secondary	Pharmacokinetic Analysis: Area under the concentration-time curve over the dosing interval (AUC(0-infinity))		Up to approximately 28 weeks
Secondary	Pharmacokinetic Analysis: Area under the concentration-time curve over the dosing interval (AUC(0-tau))		Up to approximately 28 weeks
Secondary	Pharmacokinetic Analysis: Maximum plasma concentration (Cmax)		Up to approximately 28 weeks
Secondary	Pharmacokinetic Analysis: Time to maximum plasma concentration (tmax)		Up to approximately 28 weeks
Secondary	Pharmacokinetic Analysis: Terminal elimination half-life (t1/2)		Up to approximately 28 weeks